PureIMS has announced that it intends to initiate a dose-finding study of its Levodopa Cyclops DPI titled “A pilot open-label, randomized, crossover, comparative bioavailability study of levodopa administered via Levodopa Cyclops (test product) relative to Inbrija (reference product) in healthy adult subjects” by the end of this year. In April 2023, PureIMS announced that it had completed an investment round to support development of Levodopa Cyclops for the treatment of OFF episodes in Parkinson’s disease.
The Cyclops dry powder inhaler is a pre-filled device that comes in both single-use disposable and multi-use versions. PureIMS’s pipeline also includes Cyclops DPI products with epinephrine, colistin, tobramycin, and amikacin, and the company is partnered with Radboud University on development of inhaled tigecycline. According to the current announcement, the company has recently entered into several other development agreements.
PureIMS CEO Jaap Wieling commented, “The entire team at PureIMS is very pleased with the actual start of this important clinical study. Patient studies have already proven the need for an improved levodopa dry powder inhaler and we are eager to continue the important development of Levodopa Cyclops. Levodopa Cyclops truly has the potential of becoming the best treatment option for debilitating OFF-episodes in Parkinson’s disease and to fulfill this unmet medical need.”
Read the PureIMS press release.
